|
1
|
Visvader JE and Lindeman GJ: Cancer stem
cells: Current status and evolving complexities. Cell Stem Cell.
10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kreso A and Dick JE: Evolution of the
cancer stem cell model. Cell Stem Cell. 14:275–291. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu T, Liu S, Breiter DR, Wang F, Tang Y
and Sun S: Octamer 4 small interfering RNA results in cancer stem
cell-like cell apoptosis. Cancer Res. 68:6533–6540. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu F, Li J, Chen H, Fu J, Ray S, Huang S,
Zheng H and Ai W: Kruppel-like factor 4 (KLF4) is required for
maintenance of breast cancer stem cells and for cell migration and
invasion. Oncogene. 30:2161–2172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leis O, Eguiara A, Lopez-Arribillaga E,
Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R
and Martin AG: Sox2 expression in breast tumours and activation in
breast cancer stem cells. Oncogene. 31:1354–1365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamburger AW and Salmon SE: Primary
bioassay of human tumor stem cells. Science. 197:461–463. 1977.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SY, Kang JW, Song X, Kim BK, Yoo YD,
Kwon YT and Lee YJ: Role of the IL-6-JAK1-STAT3-Oct-4 pathway in
the conversion of non-stem cancer cells into cancer stem-like
cells. Cell Signal. 25:961–969. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pattabiraman DR and Weinberg RA: Tackling
the cancer stem cells-what challenges do they pose? Nat Rev Drug
Discov. 13:497–512. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin L, Hutzen B, Lee HF, Peng Z, Wang W,
Zhao C, Lin HJ, Sun D, Li PK, Li C, et al: Evaluation of STAT3
signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast
cancer cells. PLoS One. 8:e828212013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang J, Liao D, Chen C, Liu Y, Chuang TH,
Xiang R, Markowitz D, Reisfeld RA and Luo Y: Tumor-associated
macrophages regulate murine breast cancer stem cells through a
novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells.
31:248–258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Rogoff HA, Keates S, Gao Y,
Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB and Li CJ:
Suppression of cancer relapse and metastasis by inhibiting cancer
stemness. Proc Natl Acad Sci USA. 112:1839–1844. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chesnokov V, Gong B, Sun C and Itakura K:
Anti-cancer activity of glucosamine through inhibition of N-linked
glycosylation. Cancer Cell Int. 14:452014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Contessa JN, Bhojani MS, Freeze HH,
Rehemtulla A and Lawrence TS: Inhibition of N-linked glycosylation
disrupts receptor tyrosine kinase signaling in tumor cells. Cancer
Res. 68:3803–3809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dalirfardouei R, Karimi G and Jamialahmadi
K: Molecular mechanisms and biomedical applications of glucosamine
as a potential multifunctional therapeutic agent. Life Sci.
152:21–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shiraishi A, Tachi K, Essid N, Tsuboi I,
Nagano M, Kato T, Yamashita T, Bando H, Hara H and Ohneda O:
Hypoxia promotes the phenotypic change of aldehyde dehydrogenase
activity of breast cancer stem cells. Cancer Sci. 108:362–372.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tachi K, Shiraishi A, Bando H, Yamashita
T, Tsuboi I, Kato T, Hara H and Ohneda O: FOXA1 expression affects
the proliferation activity of luminal breast cancer stem cell
populations. Cancer Sci. 107:281–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang DD, Kim YJ, Lee CN, Aggarwal S,
McKinnon K, Mesmer D, Norton J, Birse CE, He T, Ruben SM and Moore
PA: Expansion of CD133(+) colon cancer cultures retaining stem cell
properties to enable cancer stem cell target discovery. Br J
Cancer. 102:1265–1275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wanandi SI, Yustisia I, Neolaka GMG and
Jusman SWA: Impact of extracellular alkalinization on the survival
of human CD24-/CD44+ breast cancer stem cells associated with
cellular metabolic shifts. Braz J Med Biol Res. 50:e65382017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tian J, Hachim MY, Hachim IY, Dai M, Lo C,
Raffa FA, Ali S and Lebrun JJ: Cyclooxygenase-2 regulates
TGFβ-induced cancer stemness in triple-negative breast cancer. Sci
Rep. 7:402582017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ying J, Tsujii M, Kondo J, Hayashi Y, Kato
M, Akasaka T, Inoue T, Shiraishi E, Inoue T, Hiyama S, et al: The
effectiveness of an anti-human IL-6 receptor monoclonal antibody
combined with chemotherapy to target colon cancer stem-like cells.
Int J Oncol. 46:1551–1559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maley CC, Aktipis A, Graham TA, Sottoriva
A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta
KJ, et al: Classifying the evolutionary and ecological features of
neoplasms. Nat Rev Cancer. 17:605–619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wojtowicz K, Januchowski R, Nowicki M and
Zabel M: Inhibition of protein glycosylation reverses the MDR
phenotype of cancer cell lines. Biomed Pharmacother. 74:49–56.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wanandi SI, Ningsih SS, Asikin H, Hosea R
and Neolaka GMG: Metabolic interplay between tumor cells and
cancer-associated fibroblasts (CAFs) under hypoxia versus normoxia.
Malays J Med Sci. 25:7–16. 2018.
|
|
33
|
Jang BC, Sung SH, Park JG, Park JW, Bae
JH, Shin DH, Park GY, Han SB and Suh SI: Glucosamine hydrochloride
specifically inhibits COX-2 by preventing COX-2 N-glycosylation and
by increasing COX-2 protein turnover in a proteasome-dependent
manner. J Biol Chem. 282:27622–27632. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Quastel JH and Cantero A: Inhibition of
tumour growth by D-glucosamine. Nature. 171:252–254. 1953.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
He Y, Zhu Q, Chen M, Huang Q, Wang W, Li
Q, Huang Y and Di W: The changing 50% inhibitory concentration
(IC50) of cisplatin: A pilot study on the artifacts of
the MTT assay and the precise measurement of density-dependent
chemoresistance in ovarian cancer. Oncotarget. 7:70803–70821. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song KH, Kang JH, Woo JK, Nam JS, Min HY,
Lee HY, Kim SY and Oh SH: The novel oIGF-IR/Akt-dependent
anticancer activities of glucosamine. BMC Cancer. 14:312014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weimer S, Priebs J, Kuhlow D, Groth M,
Priebe S, Mansfeld J, Merry TL, Dubuis S, Laube B, Pfeiffer AF, et
al: D-Glucosamine supplementation extends life span of nematodes
and of ageing mice. Nat Commun. 5:35632014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pastò A, Bellio C, Pilotto G, Ciminale V,
Silic-Benussi M, Guzzo G, Rasola A, Frasson C, Nardo G, Zulato E,
et al: Cancer stem cells from epithelial ovarian cancer patients
privilege oxidative phosphorylation, and resist glucose
deprivation. Oncotarget. 5:4305–4319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Proffitt KD, Madan B, Ke Z, Pendharkar V,
Ding L, Lee MA, Hannoush RN and Virshup DM: Pharmacological
inhibition of the Wnt acyltransferase PORCN prevents growth of
WNT-driven mammary cancer. Cancer Res. 73:502–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chaffer CL, Brueckmann I, Scheel C,
Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y,
Polyak K, et al: Normal and neoplastic nonstem cells can
spontaneously convert to a stem-like state. Proc Natl Acad Sci USA.
108:7950–7955. 2011. View Article : Google Scholar : PubMed/NCBI
|
